Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
2019 · British Journal of Cancer · 398 citations
https://doi.org/10.1038/s41416-019-0599-y
W
Walid L. Shaib
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
191
Papers
5.5K
Citations
35
h-index
82
i10-index
Walid L. Shaib is an academic researcher from Northwest Behavioral Medicine. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Colorectal Cancer Treatments and Studies & Neuroendocrine Tumor Research Advances. The author has an h-index of 35, co-authored 163 publications.
ORCID: 0000-0001-9388-0446Papers by this author
worksDerazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
2018 · British Journal of Cancer · 375 citations
https://doi.org/10.1038/s41416-018-0334-0
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
2019 · BMC Cancer · 121 citations
https://doi.org/10.1186/s12885-019-6073-7
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
2017 · British Journal of Cancer · 93 citations
https://doi.org/10.1038/bjc.2017.330
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
2021 · Targeted Oncology · 29 citations
https://doi.org/10.1007/s11523-021-00813-6
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
2020 · British Journal of Cancer · 11 citations
https://doi.org/10.1038/s41416-020-0988-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat